Doctors prescribe Bayer’s billion-dollar blood thinner Xarelto to prevent blood clots and protect people from strokes. But the drug may also cause irreversible internal bleeding that can lead to hospitalization and death. Lawsuits filed against Bayer claim the company did not warn the public and want the drug removed from the market.
What is Xarelto?
Xarelto (rivaroxaban) is one of the newest anticoagulants more commonly known as blood thinners. The drug is an oral medication developed by Bayer and Johnson & Johnson’s Janssen Pharmaceuticals and belongs to a class of medications known as Factor Xa inhibitors. Blood thinners prevent dangerous blood clots that can obstruct the blood flow to the vital organs. Unlike older anticoagulants that require doctors to prescribe specific doses for each individual, Xarelto belongs to a new type of oral anticoagulant that is prescribed in one uniform dose.
The Food and Drug Administration (FDA) approved Xarelto for use in patients who have had knee or total hip replacement surgery to reduce the risk of blood clots and reducing the risk of stroke in people with AF. Following a fast-track regulatory review, the FDA approved the drug for general treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).